Viridian Therapeutics, Inc. VRDN

US Biotechnology

$30.64 ▲ +1.49% (+$0.45)

⬆️ Above Yest. High

Open $30.05

Prev Close $30.19

Day Range $29.25 – $30.98

52W Range $13.18 – $34.29

Market Cap $2.79B

Beta 1.06

EPS (TTM) $-3.90

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-06-18
Shares Out.	113,290,000
Website	viridiantherapeutics.com/ ↗
Phone	13026587581
Employees	252
Revenue	$25.8M
Gross Profit	$24.2M
Net Income	-$101.2M
Free Cash Flow	-$343.4M
Total Assets	$1.03B
Total Liabilities	$448.0M
Equity	$580.7M

About Viridian Therapeutics, Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Viridian Therapeutics, Inc. is a publicly traded company under the ticker symbol VRDN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.